The net profit of more than 10 pharmaceutical companies has doubled, and this company has soared more than 400 times

Recently, the first quarterly reports of 2022 have been intensively disclosed.
As of now, nearly 40 pharmaceutical companies have disclosed their first-quarter performance, and more than 80% of them are positive
.
Among them, many pharmaceutical companies doubled their net profit in the first quarter
.
It is worth noting that the net profit of Jiu'an Medical in the first quarter increased from 30 million yuan to over 10 billion yuan, a surge of more than 400 times
.
On April 12, Jiu'an Medical disclosed its performance forecast for the first quarter of 2022.
It is expected that the net profit will increase by 36707.
43% to 41965.
63% year-on-year, or about 14 billion to 16 billion yuan
.
Data show that in 2021, the net profit of Jiu'an Medical in the same period is only 38.
04 million yuan
.
Regarding the surge in performance, Jiu'an Medical said that due to the development of the epidemic in the United States, the local demand for antigen detection kit products has increased significantly.
The company's iHealth US subsidiary sells iHealth antigen detection kit products through its own channels and the Amazon platform, and cooperates with customers.
Signed major contracts and orders, the product's sales revenue growth has made an important contribution to the company's performance
.
In addition, in the first quarter of 2022, Zhifei Bio, Aotai Bio, Kaipu Bio, Tonghua Dongbao, Kangenbei, Boten, Brother Technology, Saisheng Pharmaceutical, Taienkang, Dongbao Bio and other drugs The company's net profit also doubled
.
Among them, Zhifei Bio’s first quarterly report performance forecast has increased significantly, the net profit attributable to shareholders of listed companies has increased by 90%-110% year-on-year, and the profit has been 1,782,540,300 yuan to 1,970,176,100 yuan
.
According to the analysis of relevant research reports, the market demand of Zhifei Bio HPV vaccine is strong, and it is expected to continue to grow at a high rate in 2022
.
Regarding the reasons for the changes in performance, Zhifei Bio said that the company has steadily promoted product research and development, production, promotion, and sales around its annual business goals and plans
.
The company always attaches great importance to the production and sales promotion of its own products, and continues to increase the purchase of agency products to ensure the supply of various products to meet the national disease prevention needs
.
During the reporting period, the number of batches issued by the company's main products for sale has increased significantly.
At the same time, the marketing team has actively carried out various promotion services and achieved good results.

.
In the first quarter of 2022, Tonghua Dongbao realized a year-on-year increase of 142.
63% in net profit attributable to shareholders of listed companies, or about 817 million yuan
.
Its announcement disclosed that the substantial increase in net profit in the first quarter was mainly due to the continuous growth of revenue scale and the investment income generated by the transfer of some shares of Xiamen Tebao Biological Engineering Co.
, Ltd.
through agreement transfer in the first quarter
.
If the impact of investment income is deducted, the net profit after deducting non-returning to the parent company in the first quarter continued the double-digit growth in 2021, and the company's profitability was further improved
.
Kaipu Bio is expected to make a profit of 360 million yuan to 420 million yuan in the first quarter of 2022, a year-on-year increase of 109.
38%-144.
27%
.
During the reporting period, due to the increase in demand for nucleic acid testing, the sales of sampling consumables and nucleic acid extraction reagents have been boosted, and the company's business has achieved rapid development
.
Conba expects net profit attributable to shareholders of listed companies to increase by 48.
16 million yuan to 57.
16 million yuan in the first quarter of 2022, a year-on-year increase of 100% to 120%
.
It is reported that in the first quarter of this year, Kangenbei increased its marketing efforts, and continued to carry out dynamic sales activities such as Changyanning and Jinaokang to promote the treatment of drugs and Jindi consumer experience.
The annual cooperation signing of more than 30,000 stores has effectively increased the number of chain customer orders
.
In addition, Aotai Bio is expected to achieve a year-on-year increase of 585.
4%-691.
9% in net profit in the first quarter of 2022, ranging from RMB 1.
03 billion to RMB 1.
19 billion
.
The net profit of Proton shares is expected to increase by 270%-290% year-on-year, about 326 million yuan to 344 million yuan
.
Brother Technology expects net profit to increase by 798.
89%-1068.
56% year-on-year, about 100 million-130 million yuan; Saisheng Pharmaceutical expects net profit to increase by 140%-170% year-on-year, about 102 million-115 million yuan; Tyne Kang expects net profit to increase by 217.
63%-261.
84% year-on-year, about 55.
06 million yuan to 62.
72 million yuan; Dongbao Bio expects net profit to increase by 332.
09%-461.
71% year-on-year, about 20 million yuan to 26 million yuan
.
"Testing and Calibration of Dry Body Temperature Calibrators" is about to be broadcast, welcome to sign up Disclaimer: In any case, the information or opinions expressed in this article do not constitute investment advice to anyone
.